» Articles » PMID: 18809922

Distinct Sets of Alphabeta TCRs Confer Similar Recognition of Tumor Antigen NY-ESO-1157-165 by Interacting with Its Central Met/Trp Residues

Overview
Specialty Science
Date 2008 Sep 24
PMID 18809922
Citations 23
Authors
Affiliations
Soon will be listed here.
Abstract

Naturally acquired immune responses against human cancers often include CD8(+) T cells specific for the cancer testis antigen NY-ESO-1. Here, we studied T cell receptor (TCR) primary structure and function of 605 HLA-A*0201/NY-ESO-1(157-165)-specific CD8 T cell clones derived from five melanoma patients. We show that an important proportion of tumor-reactive T cells preferentially use TCR AV3S1/BV8S2 chains, with remarkably conserved CDR3 amino acid motifs and lengths in both chains. All remaining T cell clones belong to two additional sets expressing BV1 or BV13 TCRs, associated with alpha-chains with highly diverse VJ usage, CDR3 amino acid sequence, and length. Yet, all T cell clonotypes recognize tumor antigen with similar functional avidity. Two residues, Met-160 and Trp-161, located in the middle region of the NY-ESO-1(157-165) peptide, are critical for recognition by most of the T cell clonotypes. Collectively, our data show that a large number of alphabeta TCRs, belonging to three distinct sets (AVx/BV1, AV3/BV8, AVx/BV13) bind pMHC with equal antigen sensitivity and recognize the same peptide motif. Finally, this in-depth study of recognition of a self-antigen suggests that in part similar biophysical mechanisms shape TCR repertoires toward foreign and self-antigens.

Citing Articles

Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.

Stefanidis E, Semilietof A, Pujol J, Seijo B, Scholten K, Zoete V J Clin Invest. 2024; 134(11).

PMID: 38828721 PMC: 11142748. DOI: 10.1172/JCI161660.


Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies.

Dobrin A, Lindenbergh P, Shi Y, Perica K, Xie H, Jain N Nat Cancer. 2024; 5(5):760-773.

PMID: 38503896 DOI: 10.1038/s43018-024-00744-x.


CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinity.

Baumgaertner P, Schmidt J, Costa-Nunes C, Bordry N, Guillaume P, Luescher I Front Immunol. 2022; 13:973986.

PMID: 36032094 PMC: 9399405. DOI: 10.3389/fimmu.2022.973986.


STARTRAC analyses of scRNAseq data from tumor models reveal T cell dynamics and therapeutic targets.

Bhatt D, Kang B, Sawant D, Zheng L, Perez K, Huang Z J Exp Med. 2021; 218(6).

PMID: 33900375 PMC: 8077174. DOI: 10.1084/jem.20201329.


Identification of NY-ESO-1 Specific Murine T Cell Receptors With Distinct Recognition Pattern for Tumor Immunotherapy.

Zhang H, Sun M, Wang J, Zeng B, Cao X, Han Y Front Immunol. 2021; 12:644520.

PMID: 33833762 PMC: 8021954. DOI: 10.3389/fimmu.2021.644520.


References
1.
Valmori D, Dutoit V, Lienard D, Rimoldi D, Pittet M, Champagne P . Naturally occurring human lymphocyte antigen-A2 restricted CD8+ T-cell response to the cancer testis antigen NY-ESO-1 in melanoma patients. Cancer Res. 2000; 60(16):4499-506. View

2.
Sami M, Rizkallah P, Dunn S, Molloy P, Moysey R, Vuidepot A . Crystal structures of high affinity human T-cell receptors bound to peptide major histocompatibility complex reveal native diagonal binding geometry. Protein Eng Des Sel. 2007; 20(8):397-403. DOI: 10.1093/protein/gzm033. View

3.
Romero P, Dutoit V, Lienard D, Speiser D, Guillaume P, Servis K . CD8+ T-cell response to NY-ESO-1: relative antigenicity and in vitro immunogenicity of natural and analogue sequences. Clin Cancer Res. 2001; 7(3 Suppl):766s-772s. View

4.
Valmori D, Dutoit V, Schnuriger V, Pittet M, Guillaume P, Rubio-Godoy V . Vaccination with a Melan-A peptide selects an oligoclonal T cell population with increased functional avidity and tumor reactivity. J Immunol. 2002; 168(8):4231-40. DOI: 10.4049/jimmunol.168.8.4231. View

5.
Yokosuka T, Takase K, Suzuki M, Nakagawa Y, Taki S, Takahashi H . Predominant role of T cell receptor (TCR)-alpha chain in forming preimmune TCR repertoire revealed by clonal TCR reconstitution system. J Exp Med. 2002; 195(8):991-1001. PMC: 2193687. DOI: 10.1084/jem.20010809. View